Clinical Trials Logo

Filter by:
NCT ID: NCT03729518 Active, not recruiting - Clinical trials for Squamous Cell Carcinoma

TORS De-Intensification Protocol Version 2.0: Dose and Volume Reduction in the Neck

Start date: October 11, 2018
Phase: N/A
Study type: Interventional

This is a single-arm Phase II study of adjuvant radiation for locally advanced p16+ oropharyngeal squamous cell carcinoma. The main purpose of this research is to determine the likelihood of cancer growing back in the throat or in the neck two years after completion of radiation if lower doses of radiation are used to a smaller area of the head and neck region than is currently used in standard of care.

NCT ID: NCT03729453 Active, not recruiting - Clinical trials for Intraductal Papillary Mucinous Neoplasm

Intra-operative Pancreatoscopy in Patients With IPMN

Start date: March 20, 2019
Phase:
Study type: Observational

To demonstrate the added value of intraoperative pancreatoscopy in patients undergoing partial pancreatic resection for the treatment of Intraductal Papillary Mucinous Neoplasm (IPMN) as it pertains to detection of discontinuous (skip) lesions in the remnant pancreas; to generate a hypothesis for a subsequent randomized control trial.

NCT ID: NCT03728972 Active, not recruiting - Clinical trials for NK/T-Cell Lymphoma of Nasopharynx (Diagnosis)

Study of Pembrolizumab in Patients With Early-Stage NK/T-cell Lymphoma, Nasal Type

Start date: November 9, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study is to test how well pembrolizumab shrinks Early-Stage NK/T-cell Lymphoma (ENKTL) in participants who have not yet received chemotherapy.

NCT ID: NCT03728842 Active, not recruiting - Clinical trials for Melanoma; Renal Cell Carcinoma

Spontaneous Regression in Metastatic Melanoma and Renal Cell Carcinoma

Start date: January 4, 2004
Phase:
Study type: Observational

The purpose of this study is to collect blood and clinical data from patients with metastatic melanoma and renal cell cancer who have experienced spontaneous regression for studies of immune response and other factors that may influence these occurrences.

NCT ID: NCT03728361 Active, not recruiting - Clinical trials for Neuroendocrine Tumors

Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer

Start date: December 31, 2018
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well nivolumab and temozolomide work in treating patients with small-cell lung cancer that has come back or does not respond to treatment, or neuroendocrine cancer that has spread to other places in the body. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving nivolumab and temozolomide may work better in treating patients with small-cell lung cancer and neuroendocrine cancer.

NCT ID: NCT03728257 Active, not recruiting - Exercise Clinical Trials

Lung Transplant G0 (LTGO): Improving Self-Management of Exercise After Lung Transplantation

LTGO
Start date: April 1, 2019
Phase: Phase 2
Study type: Interventional

Estimated costs, from thirty days prior to lung transplant up through six months post surgery, exceed 1 million dollars per patient and routine medical costs average approximately fifty thousand dollars per year thereafter. Prior to transplant, lung transplant recipients self restrict activity due to severe respiratory limitations, resulting in reduced muscle mass and qualitative changes in large skeletal muscles. After transplant, despite improved lung function, studies consistently report that lung recipients fail to reach predicted physical function and physical activity. Nearly seventy percent are at risk of developing hypertension within the first five years due to side effects of immunosuppression and an inactive lifestyle worsens this risk. Consequently, full benefits of transplant may not be achieved. Few studies have tested ways to engage lung recipients in self management of exercise and adopt an active lifestyle. Lung Transplant Go LTGO is a behavioral exercise intervention that provides individualized exercise training integrated with behavioral coaching delivered in the recipient's home. Exercise training will focus on assisting lung recipients to learn and practice exercises to reverse muscle conditioning. Behavioral coaching will assist them to develop the skills to self manage physical activity in daily life and maintain this as a sustained habit using strategies that include incremental goal setting, self-monitoring, feedback and problem solving.

NCT ID: NCT03727490 Active, not recruiting - Clinical trials for Arthropathy Shoulder

The Role of Subscapularis Repair in Reverse Shoulder Arthroplasty

Start date: January 2017
Phase: N/A
Study type: Interventional

The overall goal of the study is to determine if repairing the subscapularis tendon during primary reverse shoulder arthroplasty effects short-term patient outcomes. The study is a patient blinded randomized controlled trial that is currently enrolling.

NCT ID: NCT03726554 Active, not recruiting - Clinical trials for Post-Traumatic Arthritis

Post-Market Study of Comprehensive Reverse Augmented Glenoid and Mini Humeral Tray in Total Shoulder Arthroplasty

Start date: August 28, 2018
Phase: N/A
Study type: Interventional

This study is a multicenter, prospective, non-randomized, non-controlled, dual cohort post market surveillance study. The primary objective of this study is to confirm the safety and performance of the Comprehensive Reverse Shoulder System when used with the Comprehensive Porous Augmented Glenoid Baseplate and/or Comprehensive Mini Humeral Tray in primary and revision reverse shoulder arthroplasty.

NCT ID: NCT03725761 Active, not recruiting - Prostate Cancer Clinical Trials

Sacituzumab Govitecan in Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Second Generation AR-Directed Therapy

Start date: October 24, 2018
Phase: Phase 2
Study type: Interventional

This study will investigate the safety and efficacy of Sacituzumab Govitecan in patients with metastatic castration-resistant prostate cancer progressing on second generation AR-directed therapy (e.g., enzalutamide, darolutamide, apalutamide and/or abiraterone).

NCT ID: NCT03725592 Active, not recruiting - Arsenic Poisoning Clinical Trials

Strong Heart Water Study

SHWS
Start date: July 2, 2018
Phase: N/A
Study type: Interventional

Develop and evaluate the effectiveness of multi-level participatory interventions in reducing arsenic exposure among American Indian (AI) communities from North and South Dakota who participated in the Strong Heart Study (SHS).